Sanofi's bird-flu vaccine is granted FDA approval: first human treatment is seen as stopgap aid as research continues

Sanofi S.A. has obtained approval from the US Food and Drug Administration for its viral vaccine to prevent avian influenza in humans. The vaccine will not be marketed to the general public, but is expected to provide a measure of protection for workers who have a higher risk of contracting the disease.